Patch Pumps and Closed-Loop Systems Dominate Device News at ADA 2026

Automated insulin delivery systems, patch pumps and multi-purpose glucose sensors led the device news at the American Diabetes Association's 86th Scientific Sessions in New Orleans, according to a roundup published June 10 by Drug Delivery Business News.

The trade publication cited BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber, who said new trial data from Dexcom and Insulet in particular pointed to tailwinds for diabetes technology adoption. The analysts also said patch pumps were a significant part of the conversation, with Beta Bionics, Tandem Diabetes Care and MiniMed among potential entrants looking to compete with Insulet's Omnipod 5. "It is too early to determine what customers will prefer, but we think that as with all things diabetes, patients want ease-of-use, broad access, autonomy, and choice," they wrote, according to the report.

Insulet's next system

Insulet presented results from its STRIVE pivotal trial of the next-generation Omnipod 6 algorithm and from EVOLUTION 3, a feasibility study of a fully closed-loop system for type 2 diabetes, the company said in a release distributed by Business Wire, read via BioSpace. The results are company-reported conference data.

STRIVE was a randomized crossover study of 132 US participants, 98 with type 1 diabetes and 34 with type 2, comparing four weeks on Omnipod 6 at a 100 mg/dL target with four weeks on Omnipod 5 at 110 mg/dL. Insulet said time in tight range, 70 to 140 mg/dL, was 54% versus 47% for type 1 participants aged 14 and over and 48% versus 43% for type 2 participants, and that there were no instances of diabetic ketoacidosis or severe hypoglycemia. Omnipod 6 and the fully closed-loop system are investigational devices that have not been reviewed by the FDA, the company said. It plans a 510(k) filing for the closed-loop system in 2027 and a commercial launch in 2028.

Sensors, pumps and smart pens

Dexcom presented results from its CONNECT study of the G7 sensor in people with type 2 diabetes not using insulin and announced the acquisition of Nutrisense, a wellness tracking company, alongside app updates to its over-the-counter Stelo sensor, Drug Delivery Business News reported. Abbott presented data on the burden of diabetic ketoacidosis after receiving a CE mark for its dual glucose-ketone sensors, which the publication said remain investigational in the US, where the company has filed a regulatory submission.

MiniMed showed its MiniMed Flex pump, which the publication said is about half the size of the previous-generation 780G and was cleared by the FDA in March, and its MiniMed Go smart multiple-daily-injection system. Sequel Med Tech shared findings on its twiist automated insulin delivery system in type 2 diabetes, Senseonics presented real-world data on its year-long Eversense 365 implantable sensor, and Tandem presented findings supporting its expanded European CE mark. Beta Bionics, which has a patch pump called Mint in development, discussed real-world results with its iLet system.

"We expect the diabetes technology segment to continue evolving quickly, with the competitive landscape ensuring frequent product iterations, and growing awareness and access from broader reimbursement, label expansions, and outreach," the BTIG analysts said, according to the report.